先週のコメントランキング

1等 K44056800112508201626
2等 K4820979365
3等 K4841851254
4等 으마류녗
5等 K4938939996

6等 K46677049852512290744
7等 dkqlldlf
8等 데이빗백원
9等 fkwjmqke
10等 K4960300259

헤어사이트 올라온글 neosil관련 - 해석..

19年前
2,028

허접한 해석이지만.. 도움이 됐으면 합니다.

04 Jan 07
Neosil Announces Positive Phase 2 Data for NEOSH101, an Investigational Treatment for Androgenetic Alopecia

Neosil은 남성형 탈모를 위한 연구치료인 NEOSH101에 대한 긍정적인 Phase 2 data를 발표했다.

EMERYVILLE, CA -- (MARKET WIRE) -- January 04, 2007 -- Neosil, Inc., a privately held dermatology-focused pharmaceutical company, today announced positive Phase 2a clinical data demonstrating that its lead product, NEOSH101, increased hair growth significantly in men diagnosed with androgenetic alopecia, also known as pattern hair loss (PHL). Androgenetic alopecia or PHL, caused by a combination of genetic and hormonal factors, is noticeable in about 20 percent of the population by age 20 and increases steadily with age. By age 50 approximately half of the U.S. population will have some degree of PHL.*

피부질환을 바탕으로 하는 사설 제약회사인 Neosil은 주요상품인 NEOSH101이 패턴 헤어로스라고 알려진 남성형 탈모를 가진 남성에게 상당한 발모증가를 보여준다는 긍정적인 Phase 2a 임상실험 자료를 발표했다. 유전적인 요인과 호르몬 적인 요인의 결합으로 발생되는 PHL 혹은 남성형 탈모는 20대 연령층의 약 20%정도에게서 나타나고 나이의 증가에 따라 점차적으로 숫자가 늘어난다. 50세의 US 인구 절반이 PHL의 증상을 가지고 있다.

"Based on the results of this study, we are quite encouraged by the increase in hair growth observed after such a short once-daily treatment regimen with NEOSH101," said Vera H. Price, MD, FRCP(C), Professor of Clinical Dermatology, Department of Dermatology, University of California, San Francisco.

"이 연구 결과에 따르면, 우리는 NEOSH101로 하루에 한번 치료한 후 관찰한 모발 증가에 의해 상당히 고무되었다."라고 Vera H. Price, MD, FRCP(C), Professor of Clinical Dermatology, Department of Dermatology, University of California, San Francisco.이 말했다.

In a randomized, double-blind Phase 2a clinical study, conducted in Germany, 50 men with androgenetic alopecia (Norwood/Hamilton grades III-IV) received once-daily topical treatments of NEOSH101 or placebo over two 14-day treatment periods, which were separated by a one-month drug-free interval. Hair growth was measured using an objective photographic, computer-based analysis for up to 24 weeks after initiation of therapy. Results show that NEOSH101 was safe and well tolerated. A statistically significant increase in total hair count (4.8%, p=0.04), and cumulative hair thickness (3.7%, p=0.02) were observed, with peak effects occurring eight weeks following the second treatment cycle.

독일에서 시행된 무작위로 그리고 이중맹검법이 도입된 Phase 2a clinical study에서, 노우드 3~4등급 정도의 50명의 남성탈모환자들은 날마다 NEOSH101의 국소치료를 받거나 한달동안의 드럭프리 기간으로 분리되는 두번의 14일 치료과정에 Placebo(위약)을 받았다. 모발 성장은 치료가 실시된 후에 24주동안 객관적인 포토그래픽 컴퓨터 기반의 분석을 사용하여 측정되어졋다. 전체 모발수와 연속적인 모발 두께에서 통계적으로 상당한 증가가 관찰되어졌는데 이때 최고의 효과는 두번째 치료 사이클 이후인 8주째에 발생했다.

"The results of this study are encouraging, particularly the finding of increased numbers of terminal hairs, those hairs that are thicker than 40 microns and desirable for scalp coverage," said Andria Langenberg, M.D., Vice President of Clinical Development at Neosil. "We plan to initiate a Phase 2b study to evaluate daily treatment with NEOSH101 for a longer treatment period in men with PHL."

이 연구의 결과들은 특히 40micron이상의 두께를 가진 정상모의 숫자증가 발견에 고무적이고 두피 커버에 용이하다고 Andria Langenberg, M.D., Vice President of Clinical Development at Neosil가 말했다. 우리는 NEOSH101의 치료를 평가하기 위해 Phase 2b를 준비하고 있다.
About Neosil

Neosil, Inc. is a privately held dermatology-focused pharmaceutical company that was funded in November 2004 with a $32 million investment by MPM Capital and Burrill & Company, following initial incubation funding by Shalon Ventures, LP. In addition to its topical hair growth product, NEOSH101, Neosil is developing a broad-spectrum topical anti-microbial agent for acne and anti-infective use.

* Nyholt, D.R., et al.: Genetic basis for male pattern baldness, J. Investig. Dermatol. 121:1651-1564, 2003.